Sulohydroxamic acids and sulohyroxamates and their use as MEK inhibitors
US6455582B1 · kind B1 · utility
15Cited by
2References
21Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 11, 2001 |
| Grant date | Sep 24, 2002 |
| Priority date | — |
| Expiry date | Jul 11, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Sulfohydroxamic acid diarylamines of formula (I), in which the variables are as defined in the claims, are inhibitors of MEK and are effective in the treatment of proliferative diseases, cancer, stroke, heart failure, xenograft rejection, arthritis, cystic fibrosis, hepatomegaly, cardiomegaly, Alzheimer's disease, complications of diabetes, septic shock, and viral infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.